Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients.
作者信息
Nori Priya, Szymczak Wendy, Puius Yoram, Sharma Anjali, Cowman Kelsie, Gialanella Philip, Fleischner Zachary, Corpuz Marilou, Torres-Isasiga Julian, Bartash Rachel, Felsen Uriel, Chen Victor, Guo Yi
机构信息
Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Bronx NY, USA.
Department of Microbiology, Albert Einstein College of Medicine, Bronx NY, USA.
出版信息
Int J Antimicrob Agents. 2020 Dec;56(6):106179. doi: 10.1016/j.ijantimicag.2020.106179. Epub 2020 Sep 25.
Abstract
摘要
相似文献
1
Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients.新兴的共病原体：纽约市新冠肺炎患者中产生新德里金属β-内酰胺酶的肠杆菌科细菌感染
Int J Antimicrob Agents. 2020 Dec;56(6):106179. doi: 10.1016/j.ijantimicag.2020.106179. Epub 2020 Sep 25.
2
Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital.在纽约市一家医院的 COVID-19 危机期间，产碳青霉烯酶肠杆菌科细菌引起的继发性感染。
J Antimicrob Chemother. 2021 Jan 19;76(2):380-384. doi: 10.1093/jac/dkaa466.
3
Identification of a New Delhi metallo-β-lactamase-4 (NDM-4)-producing Enterobacter cloacae from a Czech patient previously hospitalized in Sri Lanka.从一名曾在斯里兰卡住院的捷克患者身上鉴定出一株产新德里金属β-内酰胺酶-4（NDM-4）的阴沟肠杆菌。
Folia Microbiol (Praha). 2013 Nov;58(6):547-9. doi: 10.1007/s12223-013-0247-5. Epub 2013 Apr 2.
4
Evidence from a New York City hospital of rising incidence of genetically diverse carbapenem-resistant Enterobacter cloacae and dominance of ST171, 2007-14.2007年至2014年期间，纽约市一家医院提供的证据表明，具有基因多样性的耐碳青霉烯类阴沟肠杆菌的发病率在上升，且ST171型占主导地位。
J Antimicrob Chemother. 2016 Aug;71(8):2351-3. doi: 10.1093/jac/dkw132. Epub 2016 Apr 26.
5
Carbapenem-heteroresistance among isolates of the Enterobacter cloacae complex: is it a real concern?阴沟肠杆菌复合体分离株中的碳青霉烯类异质性耐药：这真的值得担忧吗？
Eur J Clin Microbiol Infect Dis. 2018 Jan;37(1):185-186. doi: 10.1007/s10096-017-3138-x. Epub 2017 Nov 23.
6
Emergence of New Delhi metallo-beta-lactamase (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC-2) in South Africa.南非出现新德里金属β-内酰胺酶（NDM-1）和肺炎克雷伯菌碳青霉烯酶（KPC-2）。
J Clin Microbiol. 2012 Feb;50(2):525-7. doi: 10.1128/JCM.05956-11. Epub 2011 Nov 23.
7
Outbreak of New Delhi metallo-β-lactamase-1-producing Enterobacter cloacae in an acute care hospital general ward in Singapore.新加坡一家急症医院普通病房产新型德里金属β-内酰胺酶-1阴沟肠杆菌的暴发。
Am J Infect Control. 2016 Feb;44(2):177-82. doi: 10.1016/j.ajic.2015.08.028. Epub 2015 Oct 9.
8
Molecular characterization of metallo-β-lactamase- producing carbapenem-resistant Enterobacter cloacae complex isolated in Heilongjiang Province of China.中国黑龙江省产金属β-内酰胺酶碳青霉烯类耐药阴沟肠杆菌复合体的分子特征。
BMC Infect Dis. 2020 Jan 31;20(1):94. doi: 10.1186/s12879-020-4768-7.
9
Three cases of IMP-type metallo-β-lactamase-producing Enterobacter cloacae bloodstream infection in Japan.日本三例阴沟肠杆菌血流感染产 IMP 型金属β-内酰胺酶。
J Infect Chemother. 2013 Oct;19(5):956-8. doi: 10.1007/s10156-012-0520-6. Epub 2012 Nov 19.
10
Emergence of OXA-204 carbapenemase in Enterobacter cloacae.阴沟肠杆菌中OXA-204碳青霉烯酶的出现。
Int J Antimicrob Agents. 2019 Dec;54(6):829-830. doi: 10.1016/j.ijantimicag.2019.09.001. Epub 2019 Sep 12.
引用本文的文献
1
Influence of COVID-19 pandemic on the distribution and drug resistance of pathogens in patients with bloodstream infection.新型冠状病毒肺炎大流行对血流感染患者病原体分布及耐药性的影响
Front Public Health. 2025 Jul 28;13:1607801. doi: 10.3389/fpubh.2025.1607801. eCollection 2025.
2
Navigating the complexities of drug development for metallo-β-lactamase inhibitors.应对金属β-内酰胺酶抑制剂药物研发的复杂性。
RSC Med Chem. 2025 May 27. doi: 10.1039/d5md00035a.
3
Disease spectrum of patients with hospital-acquired multidrug-resistant organism infections in the intensive care unit: a retrospective study.重症监护病房医院获得性多重耐药菌感染患者的疾病谱：一项回顾性研究。
Front Microbiol. 2025 May 19;16:1568615. doi: 10.3389/fmicb.2025.1568615. eCollection 2025.
4
A Review on the Prevalence and Treatment of Antibiotic Resistance Genes in Hospital Wastewater.医院废水中抗生素抗性基因的流行情况与处理综述
Toxics. 2025 Mar 31;13(4):263. doi: 10.3390/toxics13040263.
5
Profile of bacterial resistance in emergency wards, non-intensive care unit areas, and intensive care units in Mexican hospitals with the antimicrobial stewardship program.墨西哥医院实施抗菌药物管理计划后，急诊病房、非重症监护病房区域和重症监护病房的细菌耐药情况
IJID Reg. 2024 Oct 24;13:100474. doi: 10.1016/j.ijregi.2024.100474. eCollection 2024 Dec.
6
Clusters of emerging multidrug-resistant organisms in US health care facilities during the initial months of the SARS-CoV-2 pandemic.在美国 SARS-CoV-2 大流行的最初几个月，医疗机构中出现了多株耐药的新兴生物体。
Am J Infect Control. 2024 Dec;52(12):1390-1396. doi: 10.1016/j.ajic.2024.07.013. Epub 2024 Jul 30.
7
Multiple impacts of the COVID-19 pandemic and antimicrobial stewardship on antimicrobial resistance in nosocomial infections: an interrupted time series analysis.2019年冠状病毒病大流行和抗菌药物管理对医院感染中抗菌药物耐药性的多重影响：一项中断时间序列分析
Front Public Health. 2024 Jul 17;12:1419344. doi: 10.3389/fpubh.2024.1419344. eCollection 2024.
8
Effects of pay-for-performance based antimicrobial stewardship on antimicrobial consumption and expenditure: An interrupted time series analysis.基于绩效支付的抗菌药物管理对抗菌药物使用及费用的影响：一项中断时间序列分析
Heliyon. 2024 Jun 8;10(12):e32750. doi: 10.1016/j.heliyon.2024.e32750. eCollection 2024 Jun 30.
9
A Case of New Delhi Metallo-ß-Lactamase-Producing Enterobacter and a Review of Cases in the United States From January 2009 to September 2022.一例产新德里金属β-内酰胺酶的肠杆菌病例及2009年1月至2022年9月美国病例回顾
Cureus. 2024 May 13;16(5):e60200. doi: 10.7759/cureus.60200. eCollection 2024 May.
10
Changing patterns of bacterial profile and antimicrobial resistance in high-risk patients during the COVID-19 pandemic at a tertiary oncology hospital.在一家三级肿瘤医院，COVID-19 大流行期间高危患者的细菌谱和抗菌药物耐药性变化模式。
Arch Microbiol. 2024 May 9;206(6):250. doi: 10.1007/s00203-024-03965-x.
本文引用的文献
1
Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge.在纽约市大流行期间住院的 COVID-19 患者中的细菌和真菌感染。
Infect Control Hosp Epidemiol. 2021 Jan;42(1):84-88. doi: 10.1017/ice.2020.368. Epub 2020 Jul 24.
2
COVID-19 and the potential long-term impact on antimicrobial resistance.COVID-19 与潜在的长期抗菌药物耐药性影响
J Antimicrob Chemother. 2020 Jul 1;75(7):1681-1684. doi: 10.1093/jac/dkaa194.
3
Bacterial and fungal infections in COVID-19 patients: A matter of concern.新冠病毒感染患者的细菌和真菌感染：一个值得关注的问题。
Infect Control Hosp Epidemiol. 2020 Sep;41(9):1124-1125. doi: 10.1017/ice.2020.156. Epub 2020 Apr 22.
4
Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020.2019 年冠状病毒病患者中某些基础健康状况的初步估计——美国，2020 年 2 月 12 日至 3 月 28 日。
MMWR Morb Mortal Wkly Rep. 2020 Apr 3;69(13):382-386. doi: 10.15585/mmwr.mm6913e2.
5
Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms.头孢地尔：一种用于治疗多重耐药革兰氏阴性菌的新型药物。
Infect Dis Ther. 2020 Mar;9(1):17-40. doi: 10.1007/s40121-020-00286-6. Epub 2020 Feb 18.
6
Infections Caused by Carbapenem-Resistant : An Update on Therapeutic Options.耐碳青霉烯类药物引起的感染：治疗选择的最新进展
Front Microbiol. 2019 Jan 30;10:80. doi: 10.3389/fmicb.2019.00080. eCollection 2019.
7
NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings.在医疗环境中 NDM 型金属β-内酰胺酶及其细菌生产者
Clin Microbiol Rev. 2019 Jan 30;32(2). doi: 10.1128/CMR.00115-18. Print 2019 Mar 20.
8
Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.头孢他啶/阿维巴坦与氨曲南联合治疗产NDM-1/OXA-48/CTX-M-15肺炎克雷伯菌感染后的临床结局
J Antimicrob Chemother. 2018 Apr 1;73(4):1104-1106. doi: 10.1093/jac/dkx496.
9
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性？
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.
10
New Delhi metallo-β-lactamase and multidrug resistance: a global SOS?新德里金属β-内酰胺酶与多重耐药性：全球发出的紧急求救信号？
Clin Infect Dis. 2011 Feb 15;52(4):485-7. doi: 10.1093/cid/ciq179.
Zotero 插件